Skip to content


Sirturo (bedaquiline) is a small molecule pharmaceutical. Bedaquiline was first approved as Sirturo on 2012-12-28. It is used to treat multidrug-resistant tuberculosis and mycobacterium infections in the USA. It has been approved in Europe to treat multidrug-resistant tuberculosis. Sirturo's patent is valid until 2029-03-19 (FDA).
Trade Name Sirturo
Common Name Bedaquiline
Indication multidrug-resistant tuberculosis, mycobacterium infections
Drug Class Antibiotics, diarylquinoline structure
Get full access now